Novocure decided to terminate Lunar-4 trial

Novocure decided to terminate Lunar-4 trial

Novocure (NASDAQ: NVCR) has announced that Spain’s Ministry of Health has made Tumor Treating Fields (TTFields) therapy available through the Spanish National Health System (SNS) for the treatment of adult patients with newly diagnosed glioblastoma. This move expands access to the innovative therapy for more patients in Spain.

The announcement comes as Novocure continues to advance its Tumor Treating Fields technology, which uses electric fields to disrupt cancer cell division. The therapy has demonstrated efficacy in treating glioblastoma, one of the most aggressive forms of primary brain cancer. TTFields therapy has already received a CE Mark for the treatment of newly diagnosed and recurrent WHO Grade 4 Glioma in adults and is commercially available in multiple countries.

According to Alvaro Nunez, General Manager of Novocure Spain, the expanded coverage will help more patients benefit from TTFields therapy. Patients with newly diagnosed glioblastoma who meet eligibility requirements defined by Spain’s Ministry of Health will be able to access TTFields therapy through hospitals and health centers qualified to offer the treatment.

TTFields therapy is administered through a wearable medical device and has shown clinical versatility when used with other cancer treatment modalities. It provides a potential solution to the treatment challenges posed by glioblastoma and other solid tumors.

Novocure’s global headquarters is located in Baar, Switzerland, with U.S. headquarters in Portsmouth, New Hampshire, and research and development facilities in Haifa, Israel. The company is committed to extending survival for patients with aggressive forms of cancer through the development and commercialization of its innovative therapy.

References:
[1] https://www.ncnewsonline.com/news/national/novocure-announces-coverage-of-tumor-treating-fields-ttfields-therapy-for-patients-with-newly-diagnosed-glioblastoma/article_10f014bc-64e4-5022-9e9d-774dd82f2dc0.html
[2] https://www.businesswire.com/news/home/20250825935932/en/Novocure-Announces-Coverage-of-Tumor-Treating-Fields-TTFields-Therapy-for-Patients-with-Newly-Diagnosed-Glioblastoma-in-Spain